Skip to content
Retail trade
KZActiveBIN 180940004081
Plans from 2 000 ₸ a month
1/17
High risk
Not present at its registered address
To risks

ТОО "КАЗФАРМАСИ"

Director
Алпысбай Абылайхан Ғабитұлы
Incorporated
04.09.2018
Address
Алматы мкр. КАЛКАМАН-2, ул. АБИШЕВА, 36/13, КОРПУС 2
РНН
600300683624

This is a company preview

Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.

The pack is not a subscription, its checks last 30 days

Risks

1/17
Not present at its registered addressHigh risk

Комитет государственных доходов · data as of 14.01.2026

This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.

Procurement signals

Court cases

Arrests & encumbrances

Enforcement proceedings

Certificates

Licenses

Profile

Summary

Full name
ТОВАРИЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "КАЗФАРМАСИ"
BIN
180940004081
Status
Active
Director
Алпысбай Абылайхан Ғабитұлы
Registration date
04.09.2018
Activity
Розничная торговля фармацевтическими товарами в специализированных магазинах, являющихся торговыми объектами, с торговой площадью менее 2000 кв.м
Legal address
Алматы мкр. КАЛКАМАН-2, ул. АБИШЕВА, 36/13, КОРПУС 2
VAT payer
Yes, since 25.02.2026
КАТО
751810000
РНН
600300683624
КФС
Собственность предприятий без государственного и иностранного участия
КСЕ
Национальные частные нефинансовые корпорации – ОПП
Company size
Малые предприятия
Employees
от 6 до 10 чел.
Procurement role
Поставщик

Activities

1
47731primary

Розничная торговля фармацевтическими товарами в специализированных магазинах, являющихся торговыми объектами, с торговой площадью менее 2000 кв.м

Download

Contacts

Change history

Financials

Tax payments

6

By year · ₸

2026
17M
2025
36M+2%
2024
35.2M+221%
2023
11M+51%
2022
7.2M+332%
2021
1.7M
·17M
2026year to date
+2%36M
2025
+221%35.2M
2024
+51%11M
2023
+332%7.2M
2022
·1.7M
2021
2026
Tax paid16,952,681 ₸
Penalty32,953 ₸
Fine0 ₸
VAT refund0 ₸
2025
Tax paid35,980,060 ₸
Penalty307,601 ₸
Fine66,614 ₸
VAT refund0 ₸
2024
Tax paid35,198,865 ₸
Penalty647,000 ₸
Fine0 ₸
VAT refund0 ₸
2023
Tax paid10,964,909 ₸
Penalty64,563 ₸
Fine0 ₸
VAT refund0 ₸
2022
Tax paid7,242,318 ₸
Penalty267,414 ₸
Fine0 ₸
VAT refund0 ₸
2021
Tax paid1,677,572 ₸
Penalty10,000 ₸
Fine0 ₸
VAT refund0 ₸
Estimated taxable profit

Estimate: corporate income tax ÷ 0%. Not a filing and not revenue — the taxable profit implied by the corporate income tax paid. Actual profit differs by deductions, carried-forward losses and reduced rates.

Download

Financial statements

Premium

Public contracts

What it sells and where

Samruk-Kazyna procurement

Tender bids

Procurement as a customer

Assets

Bank accounts

Management & owners

Leadership

1
  • АА

    Алпысбай Абылайхан Ғабитұлы

    Director

Download

Founders

Accreditations

Employees

Affiliated companies

Premium

Director's involvement in other legal entities

Branches

Relations & mentions

Company networks

Premium

Similar companies

Media mentions

Company summary

ТОО "КАЗФАРМАСИ" (BIN 180940004081) is an active legal entity in Алматы, registered in 2018 (8 years on the market). Primary activity — розничная торговля фармацевтическими товарами в специализированных магазинах, являющихся торговыми объектами, с торговой площадью менее 2000 кв.м. Automated screening found 1 risk indicator for "КАЗФАРМАСИ". Director on record — Алпысбай Абылайхан Ғабитұлы. Data current as of November 6, 2026.

Information is aggregated from open government registries of Kazakhstan: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is indexed automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the corresponding facts. This is reference information and does not replace an official extract. Learn more about the methodology and sources — SafeDeal editorial policy.